BriaCell Long Term Debt vs Net Working Capital Analysis

BCTXW Stock  USD 0.54  0.03  5.88%   
BriaCell Therapeutics financial indicator trend analysis is way more than just evaluating BriaCell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BriaCell Therapeutics is a good investment. Please check the relationship between BriaCell Therapeutics Long Term Debt and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Long Term Debt vs Net Working Capital

Long Term Debt vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BriaCell Therapeutics Long Term Debt account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between BriaCell Therapeutics' Long Term Debt and Net Working Capital is -0.47. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of BriaCell Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of BriaCell Therapeutics' Long Term Debt and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of BriaCell Therapeutics Corp are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Long Term Debt i.e., BriaCell Therapeutics' Long Term Debt and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.47
Relationship DirectionNegative 
Relationship StrengthVery Weak

Long Term Debt

Long-term debt is a debt that BriaCell Therapeutics has held for over one year. Long-term debt appears on BriaCell Therapeutics Corp balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on BriaCell Therapeutics Corp balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Net Working Capital

Most indicators from BriaCell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BriaCell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BriaCell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, BriaCell Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 8.4 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.62) in 2024.
 2021 2022 2023 2024 (projected)
Interest Income136.7K891.2K1.0M1.1M
Research Development8.0M15.3M27.2M28.5M

BriaCell Therapeutics fundamental ratios Correlations

-0.10.79-0.98-0.33-0.010.98-0.04-0.10.980.450.540.70.520.980.02-0.15-0.050.090.350.42-0.440.79-0.080.97-0.57
-0.1-0.290.17-0.750.93-0.18-0.080.93-0.190.68-0.070.010.12-0.140.90.2-0.23-0.930.220.41-0.53-0.240.93-0.27-0.59
0.79-0.29-0.80.18-0.20.80.09-0.210.8-0.06-0.060.87-0.10.77-0.26-0.180.110.22-0.140.17-0.130.98-0.20.78-0.21
-0.980.17-0.80.240.11-1.00.190.19-1.0-0.37-0.52-0.65-0.49-1.00.090.10.18-0.18-0.3-0.430.42-0.830.17-0.990.55
-0.33-0.750.180.24-0.79-0.240.13-0.7-0.23-0.98-0.56-0.06-0.7-0.3-0.860.030.260.72-0.66-0.520.650.13-0.71-0.20.79
-0.010.93-0.20.11-0.79-0.110.020.99-0.120.75-0.030.080.13-0.070.97-0.16-0.13-0.990.20.27-0.42-0.170.99-0.19-0.53
0.98-0.180.8-1.0-0.24-0.11-0.19-0.191.00.360.520.650.491.0-0.1-0.1-0.180.180.30.44-0.430.83-0.180.99-0.54
-0.04-0.080.090.190.130.02-0.190.04-0.19-0.13-0.170.27-0.19-0.20.01-0.220.98-0.03-0.2-0.330.32-0.120.04-0.190.25
-0.10.93-0.210.19-0.70.99-0.190.04-0.20.67-0.150.050.02-0.160.93-0.16-0.11-0.990.090.24-0.38-0.181.0-0.27-0.44
0.98-0.190.8-1.0-0.23-0.121.0-0.19-0.20.350.520.650.491.0-0.11-0.11-0.180.190.290.43-0.420.83-0.180.99-0.53
0.450.68-0.06-0.37-0.980.750.36-0.130.670.350.620.110.730.420.81-0.14-0.24-0.680.610.49-0.63-0.020.680.32-0.79
0.54-0.07-0.06-0.52-0.56-0.030.52-0.17-0.150.520.62-0.090.980.560.11-0.03-0.160.130.710.34-0.37-0.03-0.140.56-0.46
0.70.010.87-0.65-0.060.080.650.270.050.650.11-0.09-0.080.640.06-0.110.24-0.080.10.11-0.130.810.070.62-0.27
0.520.12-0.1-0.49-0.70.130.49-0.190.020.490.730.98-0.080.540.270.04-0.22-0.040.760.42-0.48-0.070.030.51-0.59
0.98-0.140.77-1.0-0.3-0.071.0-0.2-0.161.00.420.560.640.54-0.04-0.1-0.190.150.370.45-0.450.8-0.140.99-0.57
0.020.9-0.260.09-0.860.97-0.10.010.93-0.110.810.110.060.27-0.04-0.14-0.13-0.930.410.3-0.45-0.230.93-0.15-0.57
-0.150.2-0.180.10.03-0.16-0.1-0.22-0.16-0.11-0.14-0.03-0.110.04-0.1-0.14-0.210.120.120.25-0.24-0.16-0.15-0.14-0.22
-0.05-0.230.110.180.26-0.13-0.180.98-0.11-0.18-0.24-0.160.24-0.22-0.19-0.13-0.210.13-0.23-0.410.41-0.1-0.11-0.170.35
0.09-0.930.22-0.180.72-0.990.18-0.03-0.990.19-0.680.13-0.08-0.040.15-0.930.120.13-0.13-0.220.360.19-0.990.260.45
0.350.22-0.14-0.3-0.660.20.3-0.20.090.290.610.710.10.760.370.410.12-0.23-0.130.28-0.35-0.10.10.33-0.46
0.420.410.17-0.43-0.520.270.44-0.330.240.430.490.340.110.420.450.30.25-0.41-0.220.28-0.980.260.230.38-0.79
-0.44-0.53-0.130.420.65-0.42-0.430.32-0.38-0.42-0.63-0.37-0.13-0.48-0.45-0.45-0.240.410.36-0.35-0.98-0.21-0.37-0.370.87
0.79-0.240.98-0.830.13-0.170.83-0.12-0.180.83-0.02-0.030.81-0.070.8-0.23-0.16-0.10.19-0.10.26-0.21-0.180.81-0.27
-0.080.93-0.20.17-0.710.99-0.180.041.0-0.180.68-0.140.070.03-0.140.93-0.15-0.11-0.990.10.23-0.37-0.18-0.25-0.47
0.97-0.270.78-0.99-0.2-0.190.99-0.19-0.270.990.320.560.620.510.99-0.15-0.14-0.170.260.330.38-0.370.81-0.25-0.48
-0.57-0.59-0.210.550.79-0.53-0.540.25-0.44-0.53-0.79-0.46-0.27-0.59-0.57-0.57-0.220.350.45-0.46-0.790.87-0.27-0.47-0.48
Click cells to compare fundamentals

BriaCell Therapeutics Account Relationship Matchups

BriaCell Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets478.3K58.0M42.6M27.2M5.9M10.3M
Total Current Liabilities3.6M556.8K941.1K1.8M7.5M7.8M
Total Stockholder Equity(3.3M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Debt209.3K(57.2M)(41.0M)(21.3M)(862.1K)(905.2K)
Retained Earnings(16.6M)(15.8M)(60.3M)(80.7M)(85.4M)(81.2M)
Accounts Payable4.2K214.1K463.3K1.1M7.2M7.5M
Cash19.5K57.3M41.0M21.3M862.1K819.0K
Non Current Assets Total238.9K245.6K230.3K215.1K2.2M1.2M
Cash And Short Term Investments19.5K57.3M41.0M21.3M862.1K819.0K
Common Stock Shares Outstanding713.9K4.5M15.5M15.5M16.5M17.3M
Liabilities And Stockholders Equity478.3K58.0M42.6M27.2M5.9M10.3M
Non Current Liabilities Total142.8K225.4K31.3M29.1M1.1M1.0M
Other Stockholder Equity2.2M31.8M5.2M7.4M11.0M7.7M
Total Liab3.8M782.2K32.2M30.9M8.6M4.8M
Total Current Assets239.4K57.8M42.3M26.9M3.7M3.5M
Net Receivables20.6K12.6K24.1K717.7K1.4M1.4M
Other Current Liab3.4M342.7K477.8K677.7K290.4K275.9K
Inventory(305.0)1.0(24.1K)(18.9K)(1.4M)(1.3M)
Other Current Assets199.7K516.9K1.3M5.0M1.4M721.5K
Accumulated Other Comprehensive Income(81.0K)(94.5K)(127.0K)(138.7K)(124.8K)(118.6K)
Intangible Assets238.9K245.6K230.3K215.1K199.8K182.9K
Net Invested Capital(4.1M)57.3M10.3M(3.8M)(2.4M)(2.3M)
Net Working Capital(4.5M)57.2M41.4M25.1M(3.8M)(3.6M)
Capital Stock11.2M54.8M65.6M69.6M72.2M45.8M
Common Stock11.2M54.8M65.6M69.6M72.2M45.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.